Scarica l'app Stockscreener
0.5033
2.27%
-0.0117
Dopo l'orario di chiusura:
.50
-0.0033
-0.66%
Precedente Chiudi:
$0.515
Aprire:
$0.5051
Volume 24 ore:
8,902
Relative Volume:
0.28
Capitalizzazione di mercato:
$2.27M
Reddito:
$7,500
Utile/perdita netta:
$-9.83M
Rapporto P/E:
-0.0823
EPS:
-6.1164
Flusso di cassa netto:
$-9.33M
1 W Prestazione:
+0.96%
1M Prestazione:
-8.16%
6M Prestazione:
-48.73%
1 anno Prestazione:
-55.66%
Intervallo 1D:
$0.5025
$0.5053
Intervallo di 1 settimana:
$0.4992
$0.5223
Portata 52W:
$0.4801
$1.45
Oragenics Inc Stock (OGEN) Company Profile
Nome
Oragenics Inc
Settore
Industria
Telefono
813-286-7900
Indirizzo
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.5033 | 2.32M | 7,500 | -9.83M | -9.33M | -6.1164 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oragenics Inc Borsa (OGEN) Ultime notizie
Oragenics Faces Potential NYSE American Delisting on Equity Shortfall - Minichart
Oragenics Faces NYSE Compliance Challenges Amid Trial Progress - TipRanks
Oragenics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Oragenics (NYSE: OGEN) faces NYSE listing warning as equity falls short - Stock Titan
Oragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing Status - Quiver Quantitative
Oragenics (OGEN) Slips to $0.53, Holding Key Support Despite 1.16% DeclineRange Breakout - vinanet.vn
Oragenics: Q2 Earnings Snapshot - AOL.com
Oragenics (OGEN) flags going concern risk with $4.7M loss and $3.9M cash - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Oragenics (OGEN) Gains 2% as Micro-Cap Biotech Holds Key Support at $0.47Technical Analysis - vinanet.vn
OGEN Q2 2023 Earnings: Narrower EPS Beat Lifts Shares 2.0%Interim Report - vinanet.vn
Oragenics Q2 2023 Earnings: Narrowed Loss Surprises as Operational Efficiency ImprovesEBITDA Analysis - vinanet.vn
Oragenics Inc. Revenue Breakdown – AMEX:OGEN - TradingView
Oragenics Inc (OGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oragenics Inc (OGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oragenics Inc (OGEN) Cash Flow - TradingKey
OGEN|Oragenics Inc|Price:0.507|Chg%:-0.004 - TradingKey
TradingKey - TradingKey
Oragenics Inc (OGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
OGEN Q2 2023 Earnings: EPS Surprises to the Upside Despite No RevenueRevenue Guidance Update - vinanet.vn
OGEN Q2 2023 Earnings: EPS Beat on 50.65% Surprise but No Revenue; Stock DeclinesPost-Earnings Drift - vinanet.vn
OGEN Q2 2023 Earnings: EPS Beats Estimates by 50.65% Despite No Revenue, Stock DeclinesCost Structure Review - vinanet.vn
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineBPI Bear Correction - dars.gov.et
OGEN Q2 2023 Earnings: EPS Surprise Beats Estimates Despite Stock DeclineGuidance vs Actual - vinanet.vn
Oragenics Incto Receive Exclusive License - Moomoo
Form 4 Oragenics Inc For: 7 July By Investing.com - Investing.com Nigeria
Oragenics (OGEN) CFO receives 55,900 stock options at $0.59 exercise price - Stock Titan
ORAGENICS (OGEN) CFO reports initial holdings, including 10,000-share stock option grant - Stock Titan
Oragenics Activates All Australian Phase IIa Trial Sites for Concussion Drug ONP-002 - citybuzz -
Oragenics Achieves Full Activation of Australian Phase IIa Trial NetworkAll Three Sites Now Enrolling - The Manila Times
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling - GlobeNewswire
Oragenics Appoints New Chief Financial Officer and Leader - TipRanks
Oragenics, Inc. Announces Appointment of John Spencer to Chief Financial Officer, Effective July 1, 2026 - marketscreener.com
OGEN Q2 2023 Earnings: EPS Beat Driven by Cost Control Amid Ongoing Clinical DevelopmentEarnings Forecast Report - dars.gov.et
Price to earnings forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Narrowed Loss Surpasses Estimates, Stock Declines Amid No RevenueEarnings Quality Analysis - DonanımHaber
OGEN Q2 2023 Earnings: Narrower-Than-Expected Loss as Shares Drift LowerAnalyst Consensus Shift - po-news-eg.net
Price to book forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to EBIT forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to revenue forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Significant EPS Beat Amidst No Revenue ReportedTrough Earnings Signal - dars.gov.et
Oragenics Inc (OGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oragenics, Inc. Actuals & Estimates (AMEX:OGEN) - TradingView
Oragenics (OGEN) Sees Minor Pullback as Biotech Stock Holds Above Key SupportMA Cross Alert - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat as Operating Loss NarrowsPretax Income Report - po-news-eg.net
Oragenics Inc (OGEN) Institutional Confidence - TradingKey
Oragenics Inc. (OGEN) Holds Near $0.59 Support Amid Low Volatility – Key Levels in FocusEquity Put Call - dars.gov.et
OGENOragenics Inc Short Interest - Finviz
OGEN Q2 2023 Earnings: Narrower-than-Expected Loss Boosts Investor Sentiment Despite Stock DeclineGuidance Revision Trend - po-news-eg.net
Oragenics Inc (OGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oragenics Inc (OGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oragenics Inc Azioni (OGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):